Sterilization Methods and Selection

Sterilization methods for GMP manufacturing must be selected from the required sterility outcome, product and material characteristics, process configuration, and ability to validate and routinely control the selected process. The decision cannot be based solely on equipment availability or a general hierarchy of technologies.

Moist heat, dry heat, ethylene oxide, vaporized hydrogen peroxide, and ionizing radiation use different mechanisms of microbial inactivation. Each method has different requirements for penetration, load configuration, material compatibility, process monitoring, residual control, and validation.

Sterilizing-grade filtration may provide a sterilization step for a compatible liquid or gas, but it does not terminally sterilize a sealed final container. When terminal sterilization is not feasible, filtration must normally be integrated with controlled downstream handling and aseptic processing.

The objective is not merely to select a process capable of killing microorganisms. The selected method must:

Achieve the required sterility assurance
Reach all required product or load locations
Preserve product, component, and package quality
Operate within measurable and controllable limits
Support scientifically justified validation
Remain reproducible throughout routine operation
Be maintained through monitoring, change control, and requalification

Purpose and Scope

This article provides a framework for selecting sterilization methods for:

Finished pharmaceutical products
Drug-product containers and closures
Medical devices and combination-product components
Manufacturing equipment and product-contact parts
Single-use assemblies and process components
Laboratory and production utensils
Sterile fluid and gas pathways
Isolators, transfer chambers, and other enclosed systems

It covers the selection boundary among terminal sterilization, component sterilization, sterilizing-grade filtration, aseptic processing, and surface bio-decontamination.

Detailed cycle development and qualification requirements are addressed in the individual method articles.

What Sterilization Establishes

Sterilization is a validated process used to render a product or item free from viable microorganisms according to a defined probability of survival. It is a probabilistic process outcome rather than proof that every processed unit can be individually demonstrated to contain no microorganisms.

The required sterility assurance level depends on the product, application, regulatory framework, and applicable standard. An SAL of 10⁻⁶ is commonly applied to terminally sterilized sterile products and medical devices, but it should not be presented as an automatic universal requirement for every sterilization application.

Sterility assurance is established from an integrated body of evidence that may include:

Presterilization bioburden
Microbial resistance data
Physical process parameters
Delivered lethality or absorbed dose
Heat, gas, vapor, or radiation penetration
Load configuration
Biological-indicator or process-challenge evidence where applicable
Equipment and control-system performance
Routine-cycle monitoring
Deviation and change history

Finished-product sterility testing samples only a limited number of units and cannot independently establish a very low probability of microbial survival.

Sterilization Does Not Replace Other Controls

A validated sterilization process does not eliminate the need for upstream contamination control.

The control strategy may still require:

Raw-material and component controls
Cleaning and residue removal
Presterilization bioburden controls
Defined processing and hold times
Controlled product assembly
Suitable environmental conditions
Package or container-closure integrity
Protection from recontamination after processing
Controlled storage and distribution

Sterilization and depyrogenation also have different objectives. Sterilization targets viable microorganisms. Depyrogenation targets pyrogenic material, principally bacterial endotoxin. A process that establishes sterility does not automatically establish endotoxin control.

Terminal Sterilization Preference

Terminal sterilization treats the product in its final sealed container or final packaged configuration. This generally provides stronger sterility assurance because the microbial-inactivation step occurs after the product has been filled, closed, or packaged.

FDA guidance states that aseptic processing should be used for sterile drug products only when terminal sterilization is not feasible. The feasibility assessment must consider the product and its entire container-closure or packaging system—not the active ingredient alone. FDA’s aseptic-processing guidance provides the relevant US regulatory position.

Terminal sterilization should be evaluated first when:

The finished product can withstand the required exposure
The container-closure system remains functional
Critical quality attributes remain acceptable
Sterilant or energy can reach all required locations
A reproducible load can be defined
Process parameters can be measured and controlled
The process does not introduce unacceptable residues or degradation products

Terminal sterilization should not be selected merely because it is generally preferred. A process that damages the product, compromises package integrity, or cannot achieve reliable penetration is not technically suitable.

Terminal Sterilization, Filtration, and Aseptic Processing

Control approach	Function	Principal limitation
Terminal sterilization	Inactivates microorganisms after the product is sealed in its final container or package	Requires product and package compatibility with the exposure
Component sterilization	Sterilizes equipment parts, closures, assemblies, or other inputs before use	Sterile condition must be maintained during subsequent handling
Sterilizing-grade filtration	Removes microorganisms from a compatible liquid or gas stream	Does not sterilize the receiving container or downstream process
Aseptic processing	Maintains sterility during filtration, transfer, filling, assembly, and closure	Does not apply a final microbial-inactivation step to the sealed product
Surface bio-decontamination	Reduces biological contamination on exposed enclosure or material surfaces	May not support a sterilization claim unless the specific process is developed and validated for that outcome

Where terminal processing is not feasible, the alternative is normally an integrated aseptic control strategy rather than simple substitution of a filter for a sterilizer.

Sterilization-Method Selection Framework

Selection should proceed through five connected decisions:

Define the required outcome.
Determine whether final-container or final-package sterilization is feasible.
evaluate product, material, and package compatibility.
Demonstrate sterilant, heat, or energy penetration.
Define a practical validation and routine-control strategy.

Sterilization-method selection framework comparing moist heat, dry heat, ethylene oxide, VHP, gamma radiation, electron beam, and the boundary with sterile filtration and aseptic processing. — Sterilization-method selection begins with the required outcome and terminal-process feasibility, followed by compatibility, penetration, validation, and routine-control considerations.

The matrix should be positioned immediately before the detailed method comparison.

Comparison of Principal Sterilization Methods

Method	Suitable applications	Important selection constraints	Principal validation evidence
Moist heat	Aqueous products, porous loads, equipment parts, sealed containers, compatible components	Heat and moisture tolerance, steam contact, air removal, condensate, container pressure	Temperature distribution, heat penetration, lethality, air-removal performance, load studies and microbiological challenge
Dry heat	Glass, metal, oils, powders, and other high-temperature-compatible materials	High temperature, slower heat transfer, load density, airflow, product degradation	Empty and loaded mapping, heat penetration, exposure time, airflow, physical and microbiological evidence
Ethylene oxide	Heat- and moisture-sensitive medical devices, assemblies, packaged components and complex geometries	Humidity dependency, toxic residues, aeration, packaging permeability, emissions and material absorption	Gas concentration, humidity, temperature, pressure, half-cycle or other microbiological PQ, residual testing
VHP/VH₂O₂	Compatible medical devices, enclosed systems, transfer chambers and exposed enclosure surfaces	Distribution, line-of-sight effects, material absorption, condensation, aeration and claim boundary	Concentration, humidity, temperature, distribution studies, BI placement, leak integrity and aeration
Gamma radiation	Prepackaged products and components, including dense or complex loads	Dose effects, material degradation, product density, maximum acceptable dose and contract processing	Dose establishment, dose mapping, bioburden, dosimetry and sterilization-dose audits
Electron beam	High-throughput processing of products with suitable density and geometry	More limited penetration, conveyor configuration, beam energy, product orientation and dose uniformity	Dose establishment, beam and conveyor controls, dose mapping, dosimetry and routine dose monitoring
Sterilizing-grade filtration	Heat-sensitive liquids and gases that can pass through a suitable filter	Product compatibility, microbial retention, adsorption, fouling, integrity and downstream aseptic handling	Bacterial-retention validation, process simulation, operating limits, integrity testing and aseptic-process controls

No method is universally superior. The preferred method is the one that achieves the required microbial control with sufficient margin while preserving product quality and remaining measurable, reproducible, and controllable.

Moist Heat Sterilization

Moist heat sterilization uses moist thermal energy, commonly saturated steam, to inactivate microorganisms. Steam transfers heat efficiently when it contacts the surface or material being sterilized and when entrapped air does not interfere with exposure.

Moist heat is commonly considered first for compatible applications because it:

Provides efficient heat transfer
Uses readily measurable physical parameters
Leaves no toxic chemical sterilant residue
Supports lethality calculations
Has an extensive pharmaceutical and health-care processing history

Potential applications include:

Terminal sterilization of compatible aqueous products
Equipment parts and utensils
Porous and wrapped component loads
Stopper and closure loads
Single-use assemblies designed for steam exposure
Product-contact pathways sterilized in place

Selection must evaluate:

Product heat stability
Moisture sensitivity
Container pressure and deformation
Steam access
Air removal
Condensate accumulation
Load density and orientation
Heating and cooling effects
Required minimum and maximum lethality

A nominal chamber temperature does not demonstrate successful sterilization. The controlling question is whether the required exposure is delivered to the most difficult-to-heat location without unacceptable overprocessing elsewhere.

Dry Heat Sterilization

Dry heat sterilization uses heated air without the moisture conditions associated with steam sterilization. It is suited primarily to materials that tolerate elevated temperatures and that may be unsuitable for moist heat.

Applications may include:

Glassware
Metal components
Heat-stable utensils
Certain oils
Certain powders
Components for which moisture exposure is unacceptable

Dry heat generally requires higher temperatures or longer exposures than moist heat because heat transfer is less efficient. Selection therefore depends on:

Material temperature tolerance
Load mass and density
Airflow distribution
Heating and cooling rates
Heat penetration
Oxidation or other material effects
Equipment capacity
Reproducibility of load placement

Dry-heat sterilization and dry-heat depyrogenation must be distinguished. A dry-heat cycle may achieve both outcomes when specifically developed and validated to do so, but microbial lethality evidence does not by itself demonstrate endotoxin reduction.

Ethylene Oxide Sterilization

Ethylene oxide sterilization is a low-temperature gas process used primarily for heat- and moisture-sensitive medical devices, components, and assemblies. EtO can penetrate porous packaging and reach some complex internal pathways when the product, packaging, process, and load are properly designed.

Potential applications include:

Medical devices
Complex assemblies
Devices containing heat-sensitive polymers
Packaged components
Long or narrow internal pathways
Products requiring sterilization in a porous sterile-barrier system

Critical selection considerations include:

Product and packaging permeability
Load density
Temperature and humidity equilibration
EtO concentration
Exposure time
Gas removal
Product absorption
EtO and reaction-product residues
Aeration time
Worker and environmental controls
Contract-sterilizer governance

EtO is not selected simply because the product is heat sensitive. Residual limits, aeration duration, material absorption, emissions, processing time, and supply-chain dependence can make the method impractical.

For medical-device applications, ISO 11135:2014 remains the published standard as of this review, with a replacement edition under development. The scope of that standard should not be automatically extended to unrelated pharmaceutical applications.

Vaporized Hydrogen Peroxide

Vaporized hydrogen peroxide sterilization is a low-temperature process used for certain medical devices and contained applications. Hydrogen peroxide vapor may also be used for isolator, RABS, transfer-chamber, or room bio-decontamination.

These applications must not be assigned the same claim automatically.

A process described as surface bio-decontamination may demonstrate a specified biological reduction on exposed surfaces without establishing that every item, internal pathway, or occluded location has been sterilized. The required claim must be defined before cycle development begins.

Selection considerations include:

Required process claim
Enclosure or load geometry
Vapor distribution
Temperature and humidity
Condensation control
Material compatibility
Hydrogen-peroxide absorption
Lumen or occluded-surface access
Biological-indicator resistance and placement
Aeration and safe re-entry
Product or equipment residue limits

ISO 22441:2022 addresses low-temperature vaporized-hydrogen-peroxide sterilization of medical devices. Its medical-device scope should not be applied indiscriminately to pharmaceutical enclosure bio-decontamination.

Radiation Sterilization

Ionizing radiation damages microbial genetic material and can sterilize products after packaging. The principal industrial technologies include gamma radiation, electron beam, and X-ray processing.

Gamma Radiation

Gamma sterilization commonly uses Cobalt-60 sources and can provide substantial penetration through packaged products and comparatively dense loads.

Selection considerations include:

Product density
Load and tote configuration
Minimum and maximum dose locations
Material degradation
Color, odor, or mechanical changes
Product functionality
Dose uniformity
Source decay
Processing duration
Contract-facility controls

Electron Beam

Electron-beam sterilization uses accelerator-generated electrons. It can provide rapid processing and high throughput but generally has less penetration than gamma or X-ray processing.

Selection considerations include:

Electron energy
Product density
Product thickness
Single- or double-sided exposure
Conveyor speed
Beam scanning
Dose uniformity
Product orientation
Maximum acceptable dose

Common Radiation Considerations

Radiation method selection must establish both:

A minimum dose sufficient to achieve the required sterility assurance
A maximum dose that does not cause unacceptable product, material, or package deterioration

For medical devices, ISO 11137-1:2025 provides the current requirements for development, validation, and routine control of radiation sterilization processes.

Sterilizing-Grade Filtration

Sterilizing-grade filtration removes microorganisms from a compatible fluid stream rather than inactivating them within a final sealed unit. It is used when product characteristics prevent terminal exposure to heat, gas, or radiation.

Potential applications include:

Heat-sensitive solutions
Biologic products
Sterile gases
Process intermediates
Bulk sterile solutions before filling

Selection and validation must address:

Microbial-retention capability
Product viscosity
Filterability
Product adsorption
Extractables and leachables
Filter compatibility
Maximum pressure differential
Maximum filtration time
Maximum processed volume
Temperature
Filter fouling
Pre-use and post-use integrity testing
Redundant filtration where justified
Protection of the downstream sterile boundary

The sterile-filter lifecycle must be integrated with subsequent transfers, sterile holds, filling, closure, and environmental control. Once the product passes through the filter, any downstream exposure can reintroduce contamination.

Sterile filtration therefore does not eliminate the need for qualified aseptic filling operations.

Product and Material Compatibility

Compatibility studies must evaluate the entire exposed configuration, including:

Drug substance and formulation
Excipients
Primary container
Closure system
Device materials
Adhesives
Lubricants
Coatings
Labels
Sterile-barrier packaging
Secondary packaging exposed during processing
Sensors or electronic components
Product-contact tubing and connectors

Potential effects include:

Chemical degradation
Loss of potency
Aggregation
Oxidation
Hydrolysis
Brittleness
Discoloration
Odor formation
Dimensional change
Seal failure
Increased extractables or leachables
Loss of device performance
Loss of package integrity
Formation or retention of process residues

Compatibility should be evaluated at the maximum expected process exposure, not only at the minimum exposure required for microbial lethality. Multiple sterilization exposures must be considered when reprocessing, repeat cycles, or cumulative exposure is possible.

Penetration and Load Configuration

A sterilization process is effective only when the sterilizing condition reaches the most difficult location in the defined load.

Potential worst-case locations include:

Dense load regions
Cold spots
Long or narrow lumens
Mated surfaces
Wrapped components
Occluded surfaces
Areas containing entrapped air
Locations shielded from radiation
Materials that absorb chemical sterilant
Locations furthest from the sterilant source
Maximum-mass or minimum-load configurations

Load configuration affects:

Heat transfer
Air removal
Condensate drainage
Gas circulation
Vapor distribution
Radiation absorption
Dose uniformity
Aeration
Cooling
Process reproducibility

Routine loads must remain within the configurations and limits represented by validation. “Less than the maximum load” is not automatically less challenging. A minimum load, mixed load, partial load, or differently oriented load may create a separate worst case.

Residues and Post-Process Recovery

Chemical sterilization methods require evaluation of sterilant and reaction-product residues. Thermal and radiation processes may create degradation products even though no chemical sterilant is added.

The assessment should consider:

Residual sterilant
Reaction products
Product degradation products
Material off-gassing
Aeration or desorption time
Cooling requirements
Safe handling
Product-release testing
Storage effects
Patient exposure
Worker exposure
Environmental emissions

The cycle must include all required post-exposure phases. Aeration, cooling, pressure equalization, and safe unloading are controlled parts of the process, not optional activities performed after sterilization.

Validation Requirements Common to All Methods

Although validation evidence varies by technology, the lifecycle should normally include:

Requirements and Process Definition

Intended sterilization outcome
Product and load families
Applicable regulatory and standards framework
Required sterility assurance
Critical quality attributes
Process parameters and limits
Equipment and utility requirements
Routine monitoring and release strategy

Development

Microbial-challenge rationale
Product and material compatibility
Process penetration
Worst-case load definition
Minimum and maximum exposure
Operating ranges
Failure conditions
Process-margin evaluation

Equipment Qualification

Installation verification
Instrument calibration
Control-system verification
Alarm and interlock testing
Utility verification
Empty-equipment performance
Data acquisition and record review
Software and electronic-record controls where applicable

Performance Qualification

Defined production-equivalent loads
Physical process evidence
Microbiological or dose evidence as applicable
Worst-case locations
Repeated successful studies
Acceptance-criteria evaluation
Deviation investigation
Approved qualification report

Routine Control

Approved load configuration
Cycle-parameter review
Process indicators or dosimeters
Biological indicators where justified
Product or presterilization bioburden controls
Filter-integrity testing where applicable
Residual or release testing
Deviation handling
Batch or load release

Lifecycle Control

Periodic performance review
Calibration and maintenance
Alarm and failure trending
Change control
Supplier oversight
Contract-processor oversight
Targeted or comprehensive requalification
Continued-use assessment after significant failures

Documenting the Method-Selection Decision

The selection record should explain:

What is being sterilized.
What sterility outcome is required.
Whether terminal sterilization was evaluated.
Why candidate methods were accepted or rejected.
How product and package compatibility were assessed.
How penetration will be demonstrated.
What load configurations will be validated.
What residues or degradation effects require control.
Which standards and regulatory requirements apply.
How the process will be qualified, monitored, released, and requalified.

The decision should remain traceable to development data, risk assessments, user requirements, validation protocols, and approved operating procedures.

Common Selection Errors

Frequent weaknesses include:

Selecting the method before defining the required outcome
Rejecting terminal sterilization without documented feasibility studies
Evaluating the active ingredient but not the final container-closure system
Assuming a sterilization cycle also establishes depyrogenation
Describing all VHP applications as sterilization
Treating filtration as sterilization of the complete final process
Ignoring minimum or partial-load configurations
Failing to evaluate product and package effects at maximum exposure
Relying on chamber parameters without penetration evidence
Applying medical-device standards outside their defined scope
Assuming contract processing transfers product-quality responsibility
Failing to connect development studies to routine operating limits
Treating initial qualification as the end of validation

Regulatory and Standards Framework

For US drug manufacturing, 21 CFR 211.113(b) requires written procedures designed to prevent microbiological contamination of sterile drug products, including validation of all aseptic and sterilization processes.

FDA’s sterilization-process submission guidance describes information supporting sterilization-process efficacy in human and veterinary drug applications.

For medical devices, FDA inspection guidance emphasizes process validation, defined process parameters and tolerances, product and package effects, routine monitoring, and periodic assessment. Consensus standards may provide accepted technical frameworks, but their stated product and technology scopes must be respected.

Relevant standards include:

ISO 17665:2024 — Moist-heat sterilization of health-care products
ISO 11135:2014 and Amendment 1:2018 — EtO sterilization of medical devices
ISO 11137-1:2025 — Radiation sterilization of medical devices
ISO 22441:2022 — Vaporized-hydrogen-peroxide sterilization of medical devices
ISO 11138 series — Biological indicators
ISO 14937 — General requirements for characterization and validation of sterilizing agents and processes for medical devices

Relevant USP chapters may include General Chapters <71>, <1211>, and the <1229> sterilization series. Chapter applicability should be determined from the actual product, process, and regulatory use.

Additional requirements and standards relationships are addressed in Sterilization Regulations, Standards, and Validation Lifecycle.

Conclusion

Sterilization-method selection is a product, process, and risk decision. Terminal sterilization should be evaluated first for sterile drug products, but it is suitable only when the product, container, packaging, and required functionality remain acceptable.

Moist heat, dry heat, EtO, VHP, gamma radiation, and electron beam each impose different compatibility, penetration, monitoring, and validation requirements. Sterilizing-grade filtration is appropriate for certain heat-sensitive fluids and gases, but it transfers sterility-assurance dependence to the downstream aseptic process.

A defensible decision connects the required outcome to technical feasibility, material compatibility, worst-case penetration, process control, validation evidence, routine release, and lifecycle management.